ABVC BioPharma, Inc. (NASDAQ:ABVC) has published a corporate update and letter to shareholders from its CEO, Dr. Uttam Patil. The company has made significant progress in its clinical trials, including the development of a controlled-release tablet formulation for PDC-1421, a primary active ingredient in its neurological programs. The company has also completed feasibility studies for Vitargus®, a vitreous substitute for retinal detachment surgery, and has received approval to initiate the next phase of the trial in Australia. ABVC has also signed a licensing deal with Xinnovation Therapeutics Co., Ltd for the exclusive rights to develop, manufacture, market, and distribute its drugs for Major Depressive Disorder (MDD) and Attention-Deficit/Hyperactivity Disorder in mainland China. The deal could potentially bring in an aggregate income of $20 million for ABVC.